Phenotypic detection of Metallo-β-Lactamase in Imipenem resistant Pseudomonas aeruginosa

Carbapenems are the primary choice of treatment for severe Pseudomonas aeruginosa infection. However, the emergence of carbapenem resistance due to the production of metallo β-lactamases (MBLs) is of global concern. In this study, 90 imipenem-(IPM- or IP-) resistant P. aeruginosa (IRPA) isolates, i...

Full description

Saved in:
Bibliographic Details
Main Authors: Khosravi, Yalda, Loke, Mun Fai, Chua, Eng Guan, Tay, Sun Tee, Vadivelu, Jamuna
Format: Article
Language:en
Published: Hindawi Publishing Corporation 2012
Subjects:
Online Access:http://eprints.um.edu.my/10498/1/Phenotypic_Detection_of_Metallo-%CE%B2-Lactamase_in_Imipenem-Resistant_Pseudomonas_aeruginosa.pdf
http://eprints.um.edu.my/10498/
http://dx.doi.org/10.1100/2012/654939
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Carbapenems are the primary choice of treatment for severe Pseudomonas aeruginosa infection. However, the emergence of carbapenem resistance due to the production of metallo β-lactamases (MBLs) is of global concern. In this study, 90 imipenem-(IPM- or IP-) resistant P. aeruginosa (IRPA) isolates, including 32 previously tested positive and genotyped for MBL genes by PCR, were subjected to double-disk synergy test (DDST), combined disk test (CDT), and imipenem/imipenem-inhibitor (IP/IPI) E-test to evaluate their MBLs detection capability. All three methods were shown to have a sensitivity of 100%. However, DDST was the most specific of the three (96.6%), followed by IP/IPI E-test interpreted based on the single criteria of IP/IPI ≥ 8 as positive (62.1%), and CDT was the least specific (43.1%). Based on the data from this evaluation, we propose that only IRPA with IP MIC > 16 μg/mL and IP/IPI ≥ 8 by IP/IPI E-test should be taken as positive for MBL activity.With the new dual interpretation criteria,the MBL IP/IPI E-test was shown to achieve 100% sensitivity as well as specificity for the IRPA in this study. Therefore, the IP/IPI E-test is a viable alternative phenotypic assay to detect MBL production in IRPA in our population in circumstances where PCR detection is not a feasible option.